Navigation Links
Clinical trial seeks to cure advanced Crohn's disease using bone marrow transplant
Date:7/23/2012

SEATTLE Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

Funded by an infrastructure grant from The Eli and Edythe Broad Foundation, the initial goal of the Crohn's Allogeneic Transplant Study (CATS) is to treat a small number of patients with treatment-resistant Crohn's disease by transplanting matched bone marrow cells from a sibling or unrelated donor. Such a bone marrow transplant replaces a diseased or abnormal immune system with a healthy one.

The idea of swapping out the immune system is based on evidence that Crohn's is related to an abnormal immune response to intestinal bacteria and a loss of immune tolerance. There is strong evidence that genetic abnormalities in the immune regulatory system are linked to the disease, according to CATS principal investigator George McDonald, M.D., a transplant researcher and gastroenterologist in the Hutchinson Center's Clinical Research Division.

Although the CATS clinical trial represents a new direction for bone marrow transplantation, the procedure has precedent. The Hutchinson Center, which pioneered bone marrow and hematopoietic cell transplantation to treat blood cancers, has used allogeneic transplants to cure patients who suffered from both leukemia and Crohn's, with subsequent disappearance of the signs and symptoms of Crohn's. Similar experiences have been reported from studies done in Germany.

While autologous stem cell transplants in which the patient's own hematopoietic cells are removed and then returned after high-dose chemotherapy is given to suppress the immune system have been used to treat Crohn's patients, the benefits have not always been permanent, probably because the risk genes for Crohn's are still present. "Autologous transplantation following chemotherapy beats the disea
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 2015 Plugin creators from Pixel Film ... A fully customizable transition pack made specifically ... gives users total control over 30 transition presets built ... Pixel Film Studios. “TransFold Volume 2 gives endless possibilities ... Volume 2 from Pixel Film Studios brings back folding ...
(Date:2/28/2015)... 28, 2015 The World Scout League ... materials to potential EMTs and firefighters, recently announced its ... a way to raise charitable donations for age-related research. ... Columbia, will be held on March 29, 2015; registration ... begin at 3:30 p.m. , To participate in ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... February 27, 2015 Wireless Analytics, ... services, and one of the founders of ... for Bell Mobility within their CLEAN Platform™ (Communications ... Wireless Analytics’ newly developed Bell Mobility Data ... the Canadian wireless carrier’s business customers. , Wireless ...
(Date:2/27/2015)... A new study published in the Journal of ... on a regular basis and prostate cancer. While cycling is ... more hours per week a man spends cycling, the more ... increased importance on prostate cancer screening methods. , “This study ... at patents’ risk factors for developing prostate cancer,” says Kia ...
Breaking Medicine News(10 mins):Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3
... a novel medical,humidifier, received 510(k) clearance from the ... marketed by PARI Innovative Manufacturers,for ventilator applications. PARI ... compressors, developed the PARI,Hydrate to revolutionize the way ... reduce contamination risk for patients and give clinicians ...
... heroes fighting for treatment, ARLINGTON, Va., Dec. ... Advocacy Center today announced that Karen,Gherardini (Illinois), Janice ... annual Torrey Advocacy Commendation. The,Treatment Advocacy Center (TAC) ... to the timely and effective treatment of,severe mental ...
... Pennsylvania School of Veterinary Medicine have demonstrated the ... the cellular machinery, disrupts normal cellular function and ... for the first time that mitochondria, the cellular ... fuel, are the target of tetrachlorodibenzodioxin, or TCDD. ...
... the removal of cancer involving the tonsil region, according ... of OtolaryngologyHead & Neck Surgery, one of the JAMA/Archives ... patients with cancer through the mouth have limited access ... article. If the cancer has spread to any of ...
... Members ... -, SANTA FE, ... organization, which will help,support the needs of more than 4,000 New Mexico National ... mountain market at,TriWest, will present the check to the Adjutant General of the ...
... VICTORIA, BC, Dec. 17 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation ... that Aspreva,s,shareholders and optionholders have approved the proposed ... a wholly-owned Canadian,subsidiary, at a price of US$26.00 ... securityholders held this morning, the transaction was approved,by ...
Cached Medicine News:Health News:PARI Hydrate Receives FDA Clearance 2Health News:Treatment Advocacy Center Honors Three Grassroots Mental Illness Advocates 2Health News:Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team 2Health News:Robotic device appears useful for surgical removal of cancer involving the tonsils 2Health News:TriWest Contributes $15,000 to New Mexico National Guard Fund 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 2Health News:Aspreva obtains shareholder approval for acquisition by Galenica 3Health News:Aspreva obtains shareholder approval for acquisition by Galenica 4
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... pre-clinical study published in the Proceedings of ... ) that showed when ibrutinib (IMBRUVICA ® ) ... inhibitor), suppression of tumor growth was enhanced suggesting ... certain hematologic cancers and solid tumors with the ...
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma Corp. ... biopharmaceutical company developing therapeutic products for rare diseases, ... the European Organisation for Rare Diseases™ (EURORDIS™), The ... in observing Rare Disease Day. On ... organizations, industry, and other participants conduct special events ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... radio-frequency devices such as medical scanners and plasma generators ... increased performance and lower costs, by using the latest ... (NYSE: STM ), a global leader serving ... world leader in power semiconductors. Upgrades to ...
... of five major benefits of the new health care law, and ... To help you better understand the Affordable Care Act, which ... a web portal that explains what,s changing and when. ... Mayra Alvarez, Director of Public Health Policy in the Office of ...
Cached Medicine Technology:STMicroelectronics Reveals Best-in-Class Technology Enabling Longer-Lasting Broadcast and Medical-Imaging Equipment 2Five Benefits of the New Health Care Law 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: